MCM
BMRN icon

Marathon Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Marathon Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,500
Closed -$208K – 226
2021
Q2 		$208K Buy
+2,500
New +$198K 0.05% 186

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Marathon Capital Management's BMRN Position: Q3 2021 in Review

Marathon Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 2,500 shares — an estimated $208K sold.

Marathon Capital Management first reported a position in BMRN in Q2 2021 and held it in 1 quarter. The position peaked at $208K in Q2 2021. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

  • Marathon Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Marathon Capital Management sold 2,500 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $208K.
  • Marathon Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Marathon Capital Management's BioMarin Pharmaceuticals position peaked at $208K in Q2 2021.
  • 511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Marathon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.